Poster session IV
604: TDaP vaccination safety in pregnancy: a comparison of neonatal and obstetric outcomes among women receiving antepartum and postpartum vaccination

https://doi.org/10.1016/j.ajog.2014.10.810Get rights and content

Section snippets

Objective

We compared neonatal and obstetric outcomes among women receiving postpartum TDaP vaccination (PP TDaP) to women receiving antepartum TDaP vaccination (AP TDaP).

Study Design

We conducted a retrospective study at a university medical center. Pregnant women who received PP or AP TDaP between June 1, 2008 and May 31, 2012 were identified. Discrete maternal and neonatal variables were abstracted from the medical record and compared. Chi-square, student’s t-test, and logistic regression were used for statistical analysis.

Results

A total of 837 women who received PP TDaP and 877 women who received AP TDaP were included in the outcomes analysis. Rates of vaccination were significantly higher during the AP vaccination timeframe (45.1% vs. 27.9%, p <0.0001). Demographic characteristics such as race, maternal age, primary payor, and gestational diabetes differed between the AP and PP TDaP cohorts (p < 0.0001). The rate of preterm delivery <32 weeks of gestation was higher in PP TDaP (4.0% vs. 2.0%, p=0.02). Rates of major

Conclusion

Vaccination rates were higher in the AP timeframe. Antepartum TDaP vaccination was not associated with higher rates of congenital anomalies or other significant adverse outcomes. The higher rates of preterm delivery observed in PP TDap may reflect the shortened window of opportunity to receive AP vaccination. These findings support the safety of TDaP vaccination during pregnancy.

Table

* aOR with PP TDaP as reference group

Neonatal Composite: Apgar < 7 at 5 minutes, neonatal sepsis, very low

References (0)

Cited by (0)

View full text